The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00209027 |
Recruitment Status
:
Terminated
(difficulty with technical aspect of fMRI, resources to complete the study ran out)
First Posted
: September 21, 2005
Results First Posted
: June 18, 2012
Last Update Posted
: December 6, 2013
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia | Other: fMRI Drug: Aripiprazole | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Official Title: | Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia |
Study Start Date : | April 2005 |
Actual Primary Completion Date : | December 2010 |
Actual Study Completion Date : | April 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: schizophrenia subjects
Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.
|
Other: fMRI
fMRI scanning during behavioral reward task
Drug: Aripiprazole
30 mg by mouth once daily
|
- BOLD Activation During fMRI Scanning During Performance of a Monetary Reward Task [ Time Frame: Baseline and 12 weeks ]fMRI BOLD activation during a reward task will be compared between schizophrenia subjects and controls at Baseline. Schizophrenia subjects will switch their baseline medication to aripiprazole and their BOLD activation during the reward task at Baseline will be compared to the endpoint scan.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 50 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Subjects with Schizophrenia:
Inclusion Criteria:
- Diagnosed with schizophrenia
- Male
- Age 20-50
- Right handed
Exclusion Criteria:
- No current or past drug or alcohol problems (dependance or abuse)
- Not color blind
Control Subjects:
Inclusion Criteria:
- Male
- Age 20-50
- Right handed
Exclusion Criteria:
- No current psychiatric problems
- No current or past drug or alcohol problems
- Not color blind

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00209027
United States, Georgia | |
Atlanta VA Medical Center | |
Decatur, Georgia, United States, 30033 |
Principal Investigator: | Erica Duncan, MD | Emory University/Atlanta VA Medical Center |
Publications:
Responsible Party: | Erica Duncan, MD, Associate Professor, Emory University |
ClinicalTrials.gov Identifier: | NCT00209027 History of Changes |
Other Study ID Numbers: |
IRB00024777 570-024 ( Other Identifier: Other ) |
First Posted: | September 21, 2005 Key Record Dates |
Results First Posted: | June 18, 2012 |
Last Update Posted: | December 6, 2013 |
Last Verified: | November 2013 |
Keywords provided by Erica Duncan, MD, Emory University:
schizophrenia reward fMRI |
Additional relevant MeSH terms:
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Aripiprazole Antipsychotic Agents |
Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Psychotropic Drugs |